ProShare Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-14,662
| Closed | -$552K | – | 2456 |
|
|
2021
Q1 | $552K | Buy |
14,662
+549
| +4% | +$13.7K | ﹤0.01% | 1375 |
|
|
2020
Q4 | $240K | Buy |
+14,113
| New | +$177K | ﹤0.01% | 1755 |
|
|
2019
Q4 | – | Sell |
-13,884
| Closed | -$54K | – | 1817 |
|
|
2019
Q3 | $54K | Sell |
13,884
-192
| -1% | -$1.05K | ﹤0.01% | 1596 |
|
|
2019
Q2 | $85K | Sell |
14,076
-1,626
| -10% | -$15.5K | ﹤0.01% | 1545 |
|
|
2019
Q1 | $210K | Buy |
15,702
+154
| +1% | +$1.76K | ﹤0.01% | 1449 |
|
|
2018
Q4 | $145K | Sell |
15,548
-3,064
| -16% | -$36.5K | ﹤0.01% | 1431 |
|
|
2018
Q3 | $259K | Sell |
18,612
-555
| -3% | -$8.25K | ﹤0.01% | 1449 |
|
|
2018
Q2 | $303K | Sell |
19,167
-1,157
| -6% | -$20.2K | ﹤0.01% | 1382 |
|
|
2018
Q1 | $349K | Buy |
20,324
+701
| +4% | +$13.7K | ﹤0.01% | 1255 |
|
|
2017
Q4 | $430K | Buy |
19,623
+1,474
| +8% | +$47.4K | ﹤0.01% | 1210 |
|
|
2017
Q3 | $742K | Buy |
18,149
+972
| +6% | +$30.5K | 0.01% | 814 |
|
|
2017
Q2 | $517K | Sell |
17,177
-1,385
| -7% | -$43.2K | 0.01% | 951 |
|
|
2017
Q1 | $671K | Sell |
18,562
-4,561
| -20% | -$201K | 0.01% | 896 |
|
|
2016
Q4 | $1.16M | Buy |
23,123
+2,205
| +11% | +$116K | 0.01% | 715 |
|
|
2016
Q3 | $1.1M | Sell |
20,918
-3,372
| -14% | -$161K | 0.02% | 654 |
|
|
2016
Q2 | $1M | Buy |
24,290
+1,153
| +5% | +$50.2K | 0.01% | 717 |
|
|
2016
Q1 | $940K | Sell |
23,137
-2,281
| -9% | -$78.4K | 0.01% | 722 |
|
|
2015
Q4 | $1.05M | Buy |
25,418
+3,682
| +17% | +$123K | 0.01% | 711 |
|
|
2015
Q3 | $335K | Sell |
21,736
-1,481
| -6% | -$31.8K | ﹤0.01% | 1102 |
|
|
2015
Q2 | $577K | Sell |
23,217
-898
| -4% | -$20K | 0.01% | 1038 |
|
|
2015
Q1 | $551K | Buy |
24,115
+6,141
| +34% | +$155K | 0.01% | 1131 |
|
|
2014
Q4 | $485K | Buy |
+17,974
| New | +$309K | 0.01% | 1214 |
|
ProShare Advisors's FPRX Position: Q2 2021 in Review
ProShare Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 14,662 shares — an estimated $552K sold.
ProShare Advisors first reported a position in FPRX in Q4 2014 and held it in 22 quarters. The position peaked at $1.16M in Q4 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- ProShare Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- ProShare Advisors sold 14,662 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $552K.
- ProShare Advisors first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 22 quarters.
- ProShare Advisors's Five Prime Therapeutics, Inc. position peaked at $1.16M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.